Pfizer and BioNTech’s updated COMIRNATY vaccine, targeting the LP.8.1 COVID-19 sublineage, gained FDA approval for use in seniors and high-risk individuals aged 5 to 64. The vaccine promises enhanced immune defense against current variants and is set for immediate distribution across the U.S.
INDIANAPOLIS – Eli Lilly and Company announced that a statistically significant and clinically significant improvement in overall survival for patients with hormone receptor-positive (HR+), HER2-negative, [Read More…]
Eli Lilly announced results from the Phase 3 ATTAIN-2 trial, where its oral GLP-1 receptor agonist orforglipron provided substantial weight loss and improved A1C for adults living with obesity and type 2 diabetes demonstrating efficacy and safety consistent with injectable medicines, and moving toward regulatory approval.
The U.S. Food and Drug Administration (FDA) has broadened the approved use of Amgen’s Repatha (evolocumab) for adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C).
New Brunswick, N.J. – Over the next ten years, Johnson & Johnson (JNJ) plans to invest a staggering $2 billion to build a state-of-the-art manufacturing [Read More…]
NORTH CHICAGO, Ill – AbbVie (ABBV) has reached a significant advancement in the development of upadacitinib (RINVOQ), a JAK inhibitor for autoimmune hair loss diseases, [Read More…]
Novo Nordisk’s new studies presented at ESC Congress 2025 highlight semaglutide’s powerful cardiovascular benefits for people with diabetes and obesity, showing substantial reductions in heart attack, stroke, and cardiovascular death risks with Wegovy, Ozempic, and Rybelsus.
AbbVie has finalized its acquisition of Capstan Therapeutics, gaining access to a groundbreaking in vivo tLNP CAR-T cell therapy and proprietary RNA delivery platform for B cell-mediated autoimmune diseases.
Novo Nordisk’s Wegovy has received FDA approval to treat MASH, a serious liver disease linked to obesity and diabetes. This new indication highlights Wegovy’s role in improving liver fibrosis and reversing liver damage alongside lifestyle changes.
Omeros Corporation reported a sharply reduced net loss in Q2 2025, strengthened its balance sheet through debt restructuring and new capital, and advanced its lead drug narsoplimab toward regulatory approvals.
